77 results about "Sevelamer" patented technology

The present invention is an oral solid pharmaceutical compositions for the treatment of kidney diseases and mineral bone disorder including a phosphate binder, a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, the invention further including a method for preparing the pharmaceutical compositions including the steps of granulating cinacalcet and / or sevelamer and / or vitamin D by one of a wet and a dry granulation process, each with at least one pharmaceutically acceptable excipient to form cinacalcet granules and / or sevelamer granules and / or vitamin D granules, mixing at least two of the cinacalcet granules, sevelamer granules and vitamin D granules to form a granules mixture and compressing the granules mixture to tablets or encapsulating the granules mixture into capsules or pulverizing the granules mixture into a dispersion powder.

The present invention discloses simple process for preparation of salt of polyallylamine polymer.

The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w / w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and / or added monovalent anion source.

The invention relates to a pharmaceutical immediate release tablet comprising a core comprising 70-85 weight percent of sevelamer carbonate, calculated as an anhydrous compound, 10-25 weight percent of lactose monohydrate and, optionally, a water soluble film coat surrounding the to a process of making such tablets, to their use in medicine, and to the use of polyvinyl alcohol-polyethylene glycol graft copolymer for making such coated tablets.

The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w / w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and / or added monovalent anion source.

The invention relates to an underwater-dispersible tablet of Sevelamer carbonate, which is characterized by containing Sevelamer carbonate salt and a low-melting-point water-soluble adjuvant and is applicable to the field of medical technologies.

The invention relates to sevelamer carbonate effervescent tablets and a preparation process thereof. Each sevelamer carbonate effervescent tablet is characterized by comprising the following materials in weight percentage: 30-70% of sevelamer carbonate, 10-55% of effervescing agent, 10-40% of filling agent, 1.0-10% of adhesive, 0.1-5.0% of suspending agent, 0.5-5.0% of lubricating agent and 0.05-1.0% of corrigent. The sevelamer carbonate effervescent tablets are convenient for patients to carry and capable of overcoming patients' swallowing difficulty and has better taste, so that the patients' medication compliance can be improved. Compared with the original triturate, i.e., sevelamer carbonate tablets and dry suspension (product name: RENVELA), the sevelamer carbonate effervescent tablets have short disintegration and dispersing time in water and good dispersing effect and are easy to precipitate; and the acceleration test shows that the sevelamer carbonate effervescent tablets have good stability.

The invention provides a method for preparing sevelamer carbonate. The method comprises the following steps: a) polymerizing poly(allylamine hydrochloride) and 1, 3-dichloro-2-propanol at the temperature of between 30 and 70DEG C and the pH of 7-10, washing, and collecting the polymerized product to obtain sevelamer hydrochloride; b) dispersing the sevelamer hydrochloride in an alkali solution at the pH of 8-12 to obtain alkaline sevelamer; c) washing the alkaline sevelamer with water until neutrality to obtain an alkaline sevelamer cationic resin; and d) mixing a carbonic acid solution and the alkaline sevelamer cationic resin to obtain the sevelamer carbonate. By the method for preparing the sevelamer carbonate, the sevelamer carbonate has high purity; and in addition, by a Soxhlet extraction method, the mass transfer velocity can be improved and the reaction time is saved.

The invention discloses a method for measuring carbonic acid content in Sevelamer carbonate. The method includes: converting carbonic acid in Sevelamer carbonate to carbon dioxide in the condition of heating and / or adding excessive acid, conveying carbon dioxide into alkaline solution by aid of carrier gas, and measuring absorptive amount of carbon dioxide in alkaline solution to obtain carbonic acid content in Sevelamer carbonate. The method can effectively control the quality of Sevelamer carbonate and has the advantages of being clear in method principle, strong in specificity, high in accuracy, good in precision degree, low in cost, strong in operability and the like, and in addition, inspection devices are simple and can be obtained easily.

The invention relates to the technical field of production of sevelamer carbonate. Add an acetonitrile solution of epichlorohydrin to the solution of polyallylamine hydrochloride in proportion, and obtain a polymerized jelly after curing; after polymerization, the jelly is ground to 50 mesh by a colloid mill and then added 4% Hydroxide Sodium aqueous solution, stirred and reacted to obtain sevelamer base; finally, purified water was added to the sevelamer base, the temperature was raised, carbon dioxide was fed in, the mixture was kept warm, stirred and reacted, centrifuged and dried to obtain sevelamer carbonate. Adopting the preparation process of the sevelamer carbonate of the present invention can greatly reduce product energy consumption, improve product quality, and solve the problem of waste water generation; meanwhile, it can also reduce labor intensity and improve labor productivity. To improve product quality, the qualified rate of finished products reached 99.6%, and the yield reached 64.7%.

The invention relates to a measuring method of the carbonate content in sevelamer carbonate, and belongs to the technical field of medicine quantitative analysis. The method comprises the following steps: (1) installing a carbon dioxide generating device and an absorption device; (2) preparing a barium oxide absorption solution; (3) precisely weighing 1g of sevelamer carbonate, and adding the sevelamer carbonate into the carbon dioxide generating device; (4) adding the barium oxide absorption solution into the absorption device; (5) adding sulfuric acid into the sevelamer carbonate in the step (3); (6) performing titration on the barium oxide absorption solution by hydrochloric acid, and calculating the carbonate content in the sevelamer carbonate. The measuring method has the advantages that simplicity, convenience and high speed are realized; the cost is low; the accuracy and the precision are high; the measuring method is more suitable for daily quality management by a production department.

A method for treating hyperglycemia and / or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

The invention belongs to the field of pharmacy, and relates to a sevelamer carbonate crude drug for preparing tablets, a preparation method and application of the sevelamer carbonate crude drug. The particle size of the sevelamer carbonate crude drug meets the conditions: D 0.95 is less than or equal to 180mu m, D 0.50 is less than or equal to 50mu m, and D 0.05 is more than or equal to 9mu m at the same time. The polyallylamine carbonate has the soluble oligomer (0.2%) within the particle size range. The tablets prepared from the sevelamer carbonate crude drug have the advantages of being smooth in surfaces, good in hardness and low in friability.

The present invention relates to a process for the preparation of cross-linked polyallylamine or a pharmaceutically acceptable salt thereof. The present invention also relates to preparation of sevelamer or a pharmaceutically acceptable salt thereof which is used in the treatment of hyperphosphatemia and has good fluidity, low porosity and / or a swelling index of 7 to 9 method, the pharmaceutically acceptable salt is preferably hydrochloride or carbonate.